More Highlights From the 2003 Retrovirus Conference
We know that women are at greater risk for developing bone problems
than men, but could HIV infection or HAART make these problems worse?
Dr. Andy Pavia reports on the latest research into bone disorders
among HIV-positive women.
Once-daily ddI (didanosine, Videx EC) can be taken with tenofovir
(Viread) at the same time with a light meal, provided the dose of
ddI is reduced from 400 mg to 250 mg, researchers say. Dr. Edwin
DeJesus has the details.
Tipranavir is one of several HIV drugs in the works that researchers
hope will provide new treatment options to people who are resistant
to many of the meds currently on the U.S. market. Dr. David Wohl
reports on the latest tipranavir research.
Browse through the rest of The Body's Retrovirus coverage by
visiting this page!
Other Sources Cover Retrovirus 2003
Since the Retrovirus conference was so massive, no single
organization could possibly cover the entire thing. We'll post
everything we can find about the conference, though: Here's an
overview of new antiretrovirals from well-known treatment
advocate Jules Levin.
You'll continue to see lots of news from this conference coming
from a wide range of sources. Visit our "Conference News From Other Sources" page to stay on top of it all!
Who Will Pay for Your T-20?
$20,000 per year -- that's how much it'll cost European health plans
to provide HIV-positive patients with twice-daily injections of T-20
(enfuvirtide, Fuzeon). The new HIV drug, which is aimed at people
whose other HIV drug regimens have failed, could be approved for use
in the U.S. as early as March. The question is: Will Medicaid, ADAP
and health insurance companies balk at paying the bill?
Another Disappointment on the AIDS Vaccine Front
The first HIV vaccine tested in a large at-risk population has
proven to be largely ineffective, but there's an interesting catch:
The vaccine appeared to have some protective effect within a small
group of non-Hispanic minorities.
New HIV Drugs in Old Drug Classes
Although T-20 and other so-called "entry inhibitors" are part of an
exciting new family of HIV drugs, there are many drugs in development
that improve on drug families we're already familiar with -- protease
inhibitors, NRTIs and NNRTIs. ACRIA provides a rundown.
Which Is Better: Once-a-Day or Twice-a-Day HIV Meds?
Once-a-day drugs: Sure, they seem easier, but should everybody choose
them over two- or three-times-a-day drugs? ACRIA takes a closer look.
Easing Lipodystrophy in Women
Doctors still aren't sure how lipodystrophy can be treated, but there
are some steps women can take to lessen the symptoms. ACRIA's
"Treatment Issues for Women" guide provides some tips.
"Salvaging" Your HIV Therapy
Doctors call it "salvage" therapy; treatment advocates call it
"rescue" therapy -- it's what you do when most of the available HIV
drugs no longer work against the virus in your body. For an in-depth
look at why HIV treatments fail and how "salvage" therapy works,
read this article.
Prostate Cancer a Greater Concern in Black Men
It may be especially hard for doctors to diagnose prostate cancer
early in HIV-positive black men, a recent study found. As a result,
black men with HIV who are over 40 should be extra diligent about
getting screened for prostate cancer.
A Gay Native American's Life With HIV
Johnny Changingwolf, a gay HIV-positive half-Apache, half-Navajo,
was a man who "walked between worlds." Read the story of how art therapy brought Johnny back from life's precipice.
Government Backs Off Gay Safe-Sex Program
U.S. health officials have given the thumbs-up to controversial
workshops run by the Stop AIDS Project in San Francisco. A
Republican Congressman had accused them of promoting sexual
activity in violation of government guidelines; an earlier
government report called the workshops "obscene."
Why Prison Authorities Don't Like HIV Treatment Educators
Prison services coordinator Hugo Mendez talks about the fine line
an HIV treatment educator must walk in the U.S. prison system:
"Because there is the potential for informed prisoners to advocate
for specific (and often expensive) medications by name,
administrators look at education as a hindrance in the system."
Organ Transplants Safe in People With HIV
Now that HIVers are living longer than ever, the number of organ transplants in people with HIV is on the rise. A recent study looked at the risks of kidney and liver transplants in HIVers, and found encouraging results.
Kaletra: The Toughest PI There Is
Kaletra (a combination of two drugs, lopinavir and ritonavir) is
widely considered the most powerful protease inhibitor on the market
today. To learn more about it, click here.
Interleukin-2, What Are You?
It's the experimental HIV treatment that just won't go away: Project
Inform updates us on the trials and tribulations of Interleukin-2, an immune-based therapy with a very rocky history.
A Selection of the Top HIV/AIDS Stories From Across the Internet:
Lessons From Uganda's AIDS Success Story
Six percent of the population has HIV, a much lower percentage than
in most of sub-Saharan Africa
From The Daily News (Harare) (February 26, 2003)
Nevirapine Studied as Pre-Exposure Prophylaxis for HIV
Early trials suggest a low dose of the drug may be safely used in
From AIDS Map (February 25, 2003)
Three Times as Many People Living With HIV/AIDS in Middle East, West Asia Than Three Years Ago, WHO Reports
Since 1999, the number of HIV-positive people in these areas has
risen from 220,000 to 700,000
From Kaiser Daily HIV/AIDS Report (February 24, 2003)
More often than ever before, women with HIV in the U.S. can now
have HIV-negative babies, peace of mind during pregnancy and hope
for a long, healthy motherhood
From POZ Magazine (December 2002)